Ajanta Pharma
Ajanta Pharma
Shareholder Return: 3-year, Sales Growth: 3-year CAGR, Return On Equity: 3-year average
At a Glance
-
Shareholder Return724%
-
Sales Growth23%
-
Return on Equity43 %
Why Super 50
Brothers Yogesh and Rajesh Agrawal have transformed the ailing, legacy business started by their father and uncles in 1973 into a generic drug maker of reckoning by focussing on niche, specialty generic drugs. Ajanta's growth has come from markets like Asia and Africa so far, and the company now plans to create a bigger footprint in the US, the world's largest generic drugs market.
